Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France
Sign Up to like & getrecommendations! Published in 2018 at "Osteoporosis International"
DOI: 10.1007/s00198-018-04821-7
Abstract: SummaryThe use of gastro-resistant risedronate, a convenient dosing regimen for oral bisphosphonate therapy, seems a cost-effective strategy compared with weekly alendronate, generic risedronate, and no treatment for the treatment of postmenopausal women with osteoporosis in… read more here.
Keywords: alendronate generic; treatment; risedronate treatment; risedronate ... See more keywords
Comparison of the efficacy between once-monthly oral ibandronate and risedronate among Korean women with osteoporosis: a nationwide population-based study
Sign Up to like & getrecommendations! Published in 2018 at "Osteoporosis International"
DOI: 10.1007/s00198-018-4778-0
Abstract: SummaryUsing a nationwide database from the Korean National Health Insurance Service, this study showed that once-monthly oral ibandronate (150 mg) had better anti-fracture efficacy than once-monthly oral risedronate (150 mg), as seen on assessing overall and non-vertebral… read more here.
Keywords: among korean; ibandronate; efficacy monthly; monthly oral ... See more keywords
Efficacy of teriparatide compared with risedronate on FRAX®-defined major osteoporotic fractures: results of the VERO clinical trial
Sign Up to like & getrecommendations! Published in 2020 at "Osteoporosis International"
DOI: 10.1007/s00198-020-05463-4
Abstract: FRAX® calculates the 10-year probability of major osteoporotic fractures (MOF), which are considered to have a greater clinical impact than other fractures. Our results suggest that, in postmenopausal women with severe osteoporosis, those treated with… read more here.
Keywords: frax defined; risedronate; osteoporotic fractures; frax ... See more keywords
Phase II/III, randomized, double-blind, parallel-group study of monthly delayed-release versus daily immediate-release risedronate tablets in Japanese patients with involutional osteoporosis
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Bone and Mineral Metabolism"
DOI: 10.1007/s00774-019-01031-x
Abstract: Absorption of oral immediate-release (IR) risedronate tablets is reduced by food intake, thus a delayed-release (DR) tablet has been developed to overcome the necessity of taking IR tablets under fasting conditions. This randomized, double-blind, phase… read more here.
Keywords: phase; immediate release; breakfast; following breakfast ... See more keywords
Serum 25-hydroxy-vitamin D and the risk of fractures in the teriparatide versus risedronate VERO clinical trial
Sign Up to like & getrecommendations! Published in 2019 at "Archives of Osteoporosis"
DOI: 10.1007/s11657-019-0561-x
Abstract: PurposeUsing data from the 2-year, randomized, double-dummy VERO trial, we examined the changes in 25-hydroxy-vitamin D (25[OH]D) concentrations over time, and whether the fracture risk reduction of teriparatide versus risedronate varies by baseline 25(OH)D sufficiency… read more here.
Keywords: risk; trial; teriparatide versus; risedronate ... See more keywords
Efficacy of risedronate with cholecalciferol on bone mineral density in Korean patients with osteoporosis
Sign Up to like & getrecommendations! Published in 2019 at "Archives of Osteoporosis"
DOI: 10.1007/s11657-019-0663-5
Abstract: The efficacy of once-weekly risedronate with and without cholecalciferol in bone mineral density (BMD) in Korean patients with osteoporosis was compared. After 12 months, both spine and hip BMD increased significantly in both groups, but… read more here.
Keywords: bmd; rsd group; korean patients; risedronate ... See more keywords
The prevention and treatment of glucocorticoid-induced osteopaenia in juvenile rheumatic disease: A randomised double-blind controlled trial☆
Sign Up to like & getrecommendations! Published in 2019 at "EClinicalMedicine"
DOI: 10.1016/j.eclinm.2019.06.004
Abstract: Background Children and young people (CYP) with chronic rheumatic conditions; Juvenile Idiopathic Arthritis, Juvenile Systemic Lupus Erythematosus, Juvenile Dermatomyositis and Juvenile Vasculitis, treated with steroids, have low bone density, increased fracture risk and are likely… read more here.
Keywords: controlled trial; prevention treatment; risedronate; placebo ... See more keywords
Efficacy of topical risedronate and risedronate - Eudragit E complex in a model of cutaneous leishmaniasis induced by Leishmania (Leishmania) amazonensis
Sign Up to like & getrecommendations! Published in 2021 at "Heliyon"
DOI: 10.1016/j.heliyon.2021.e07136
Abstract: An efficacious topical treatment for cutaneous leishmaniasis (CL) is highly desirable but still an ongoing challenge. Systemic risedronate (Ris) has been reported to have anti-leishmanial properties and Eudragit EPO (EuE) has shown in vitro activity… read more here.
Keywords: amazonensis; efficacy topical; ris; risedronate ... See more keywords
Anionic versus cationic bilosomes as oral nanocarriers for enhanced delivery of the hydrophilic drug risedronate.
Sign Up to like & getrecommendations! Published in 2019 at "International journal of pharmaceutics"
DOI: 10.1016/j.ijpharm.2019.04.069
Abstract: Albeit its well known potency as a postmenopausal osteoporosis treatment, Risedronate suffers from poor oral bioavailability and high oral toxicity. This is the first work to assess the potential of bilosomes to address challenges of… read more here.
Keywords: delivery; toxicity; cationic bilosomes; drug ... See more keywords
Efficacy of risedronate in improving bone mineral density in patients undergoing total hip arthroplasty
Sign Up to like & getrecommendations! Published in 2018 at "Medicine"
DOI: 10.1097/md.0000000000013346
Abstract: Background: Risedronate is widely used in the therapy of osteoporosis and other metabolic bone diseases. This meta-analysis was aimed to assess whether administration risedronate could increase the bone mineral density (BMD) in patients undergoing primary… read more here.
Keywords: bone mineral; hip; risedronate; patients undergoing ... See more keywords
Risedronate therapy in patients with mild-to-moderate chronic kidney disease with osteoporosis: post-hoc analysis of data from the risedronate phase III clinical trials
Sign Up to like & getrecommendations! Published in 2017 at "BMC Nephrology"
DOI: 10.1186/s12882-017-0478-9
Abstract: BackgroundThe clinical effect of bisphosphonate treatment has not been clearly evaluated by kidney function in Japanese Chronic Kidney Disease (CKD) patients with osteoporosis. This study analyzed the data from three risedronate Japanese phase III trials.… read more here.
Keywords: chronic kidney; kidney disease; risedronate therapy; risedronate ... See more keywords